Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ: IVVD )

2.500 -0.010 (-0.40%)
Streaming Delayed Price Updated: 10:17 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,457
Open 2.460
Bid (Size) 2.490 (6)
Ask (Size) 2.500 (1)
Prev. Close 2.510
Today's Range 2.400 - 2.520
52wk Range 0.9802 - 5.195
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
From Invivyd
Via GlobeNewswire
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire

Performance

YTD
-31.51%
-31.51%
1 Month
-18.30%
-18.30%
3 Month
-48.77%
-48.77%
6 Month
+67.79%
+67.79%
1 Year
+113.68%
+113.68%

More News

Read More
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position
From Invivyd
Via GlobeNewswire
IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023
Via InvestorPlace
Invivyd: Q4 Earnings Insights
Via Benzinga
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™
From Invivyd
Via GlobeNewswire
Invivyd Announces CEO Transition
From Invivyd
Via GlobeNewswire
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million
From Invivyd
Via GlobeNewswire
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune System
Via Benzinga
Exposures COVID-19 Product Safety
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
From Invivyd
Via GlobeNewswire
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
From Invivyd
Via GlobeNewswire
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Invivyd
Via GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
Via InvestorPlace
Apple To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.